Wells Fargo’s Editas Medicine EDIT Stock Holding History

Wells Fargo’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$887K	–	7699
2022 Q4	$887K	Buy	100,000 +73,500	+277%	+$807K	﹤0.01%	3314
2022 Q3	$324K	Hold	26,500	–	–	﹤0.01%	3964
2022 Q2	$313K	Hold	26,500	–	–	﹤0.01%	4033
2022 Q1	$504K	Hold	26,500	–	–	﹤0.01%	4403
2021 Q4	$704K	Hold	26,500	–	–	﹤0.01%	4401
2021 Q3	$1.09M	Buy	+26,500	New	+$1.45M	﹤0.01%	4173

Other funds holding EDIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo's EDIT Position: Q1 2026 in Review

Wells Fargo reduced its Editas Medicine (EDIT) stake by 37% in Q1 2026, selling an estimated $128K and leaving 102,030 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #4571.

Wells Fargo first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $11.2M in Q2 2021. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Wells Fargo held 102,030 shares of Editas Medicine worth $252K as of Q1 2026.
Wells Fargo sold 60,714 Editas Medicine shares in Q1 2026, an estimated $128K.
Editas Medicine made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4571 holding.
Wells Fargo first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
Wells Fargo's Editas Medicine position peaked at $11.2M in Q2 2021.
208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.